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Abstract
Background: Recently, several lines of evidence have shown the aberrant expression of cell-cycle-related proteins
and tumor suppressor proteins in vulnerable neurons of the Alzheimer’s disease (AD) brain and transgenic mouse
models of AD; these proteins are associated with various paradigms of neuronal death. It has been reported that
ATBF1 induces cell cycle arrest associated with neuronal differentiation in the developing rat brain, and that gene
is one of the candidate tumor suppressor genes for prostate and breast cancers in whose cells overexpressed
ATBF1 induces cell cycle arrest. However, the involvement of ATBF1 in AD pathogenesis is as yet unknown.
Results: We found that ATBF1 was up-regulated in the brains of 17-month-old Tg2576 mice compared with those
of age-matched wild-type mice. Moreover, our in vitro studies showed that Ab1-42 and DNA-damaging drugs,
namely, etoposide and homocysteine, increased the expression ATBF1 level in primary rat cortical neurons, whereas
the knockdown of ATBF1 in these neurons protected against neuronal death induced by Ab1-42, etoposide, and
homocysteine, indicating that ATBF1 mediates neuronal death in response to these substances. In addition, we
found that ATBF1-mediated neuronal death is dependent on ataxia-telangiectasia mutated (ATM) because the
blockage of ATM activity by treatment with ATM inhibitors, caffeine and KU55933, abolished ATBF1 function in
neuronal death. Furthermore, Ab1-42 phosphorylates ATM, and ATBF1 interacts with phosphorylated ATM.
Conclusions: To the best of our knowledge, this is the first report that Ab1-42 and DNA-damaging drugs
increased the ATBF1 expression level in primary rat cortical neurons; this increase, in turn, may activate ATM
signaling responsible for neuronal death through the binding of ATBF1 to phosphorylated ATM. ATBF1 may
therefore be a suitable target for therapeutic intervention of AD.
Background
Alzheimer’s disease (AD), a progressive neurodegenera-
tive disorder of the elderly, is associated with a chronic
loss of synapses and neuronal death, and is character-
ized by the presence of parenchymal deposits of amy-
loid-b peptides (Ab), the major protein component of
senile plaques [1,2]. Accumulation of Ab in the brain is
associated with disease-causing inherited variants of the
amyloid precursor protein (APP) [3], presenilin 1 (PS1)
[4], presenilin 2 (PS2) [5], and apoplipoprotein E
(APOE) [6] genes, and an increased extracellular Ab
level is a major cause of neuronal death in AD. In addi-
tion to genetic evidence that Ab promotes neuronal
degeneration and death in vivo [7,8], in vitro studies
show that Ab aggregates rapidly induce neuronal death
by necrosis or apoptosis [9,10], and Ab-induced neuro-
toxicity involves oxidative stress, inflammation, and per-
turbation of calcium homeostasis [1]. However, the
mechanisms by which neuronal degeneration and death
o c c u ri nA Da n dw h e t h e rt h e ya r ei n d u c e db yA b are
not completely understood.
One focus in the mechanism of neuronal death in AD
is the aberrant expression of cell-cycle-related proteins,
such as cdc2, cdk4, cyclin B1, and cyclin D, which med-
iate cell cycle progression, in vulnerable neurons of the
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in neuronal death associatedw i t hv a r i o u sp a r a d i g m so f
neuronal death [15]. In addition to cell cycle progres-
sion molecules, a number of cell cycle inhibitors, such
as p16 and p27 [13,16], and tumor suppressor proteins
such as p53 and BRCA1 [17,18] are also increased in
levels in the AD brain. In addition to the human AD
brain, the increased expression levels of cell-cycle-
related proteins were also found in transgenic mouse
models of AD [19,20]. Although it is unclear why cell-
cycle-related proteins show increased in levels in the
AD brain and AD mouse models, one possibility is
that DNA damage induced by Ab m a yi n c r e a s et h e
levels of or activate these molecules. Indeed, DNA
damage was found in the AD brain, and Ab increases
Cdc25A [21], Cdk4, and p53 [22] levels in primary rat
neurons resulting in neuronal death. Recently, Kruman
et al. have reported that cultured postmitotic cortical
neurons exposed to Ab undergo apoptosis that is
dependent on tumor suppressor factor ataxia-telangiec-
tasia mutated (ATM) activity, whereas treatment with
caffeine, which is an ATM inhibitor, can exert a neu-
roprotective effect on cultured neurons exposed to Ab
[22]. In this context, ATM appears to potentiate neu-
ronal apoptosis.
AT-motif binding factor 1 (ATBF1) is a 404 kDa tran-
scription factor that contains 4 homeodomains and 23
zinc-finger motifs [23] involved in transcription regula-
tions and protein-protein interactions [24]. We pre-
v i o u s l yr e p o r t e dt h a tA T B F 1i sh i g h l ye x p r e s s e di n
postmitotic neurons but not in neural progenitor cells,
and it induces cell cycle arrest associated with neuronal
differentiation in the developing rat brain [25]. We also
found that sublocalization of ATBF1 is regulated by
phospatidylinositol-3 (PI3) kinase including ATM [25],
indicating that ATBF1 is one of the targets of ATM.
Indeed, ATM phosphorylates ATBF1 at Ser1180 in
HEK293T cells exposed to 10-Gy radiation [26]. ATBF1
also interacts with p53 to activate the p21
Waf1/Cip1 pro-
moter to trigger cell cycle arrest [27]. It has also been
reported that the ATBF1 gene is one of the candidate
tumor suppressor genes for prostate and breast cancers
in whose cells overexpressed ATBF1 induces cell cycle
arrest [28,29]. However, the involvement of ATBF1 in
AD pathogenesis is as yet unknown.
In this study, we investigated whether ATBF1 expres-
sion is altered in the brains of Tg2576 mice similarly to
other cell-cycle-related molecules, and we found an up-
regulated ATBF1 expression in the brains of Tg2576
mice compared with those of age-matched wild-type
mice. Moreover, our in vitro studies showed that Ab
and DNA-damaging drugs, namely, etoposide and
homocysteine, increased the ATBF1 expression level in
primary rat cortical neurons; this increase, in turn, may
activate ATM signaling responsible for neuronal death
through the binding of ATBF1 to phosphorylated ATM.
Results
ATBF1 was up-regulated in the brains of 17-month-old
Tg2576 mice compared with those of age-matched wild-
type mice
W ef i r s ti n v e s t i g a t e dw h e t h e rA T B F 1e x p r e s s i o ni s
altered in the brains of Tg2576 mice overexpressing
human APP with the Swedish mutation. Total proteins
were extracted from whole brains of 10- and 17-month-
old Tg2576 and age-matched wild-type mice, and sub-
jected to Western blot analysis. We found that the
ATBF1 expression level in the brains of 17-month-old
wild-type mice was lower than that in the brains of 10-
month-old wild-type mice. However, ATBF1 expression
was significantly up-regulated in 17-month-old Tg2576
mice compared with age-matched wild-type mice,
whereas there was no significant difference between
Tg2576 and wild-type mice at the age of 10 months
(Figure 1).
Ab1-42 and DNA-damaging drugs, etoposide and
homocysteine, increased ATBF1 expression level in
cultured rat cortical neurons
In Tg2576 brains, the accumulation of Ab occurs from 15
to 23 months but is not observed in appreciable amounts
until 12 months [30]. Therefore, we hypothesized that an
increase in ATBF1 expression level in the brains of 17-
month-old Tg2576 mice is due to an increase in Ab level.
To test this hypothesis, we determined by Western blot
analysis the protein expression levels of ATBF1 and p53,
which play a key role in the regulation of cell viability in
response to DNA-damaging drugs in many cell types
including neurons, in cultured rat cortical neurons treated
with 10 μMA b1-42 for 16 h. The Ab1-42 peptide used in
our experiments was largely monomer (see “Additional
file 1“). We observed that Ab1-42 significantly increased
ATBF1 and p53 protein expression levels in these cells
(Figure 2A). A previous study showed that the expression
level of ATBF1 is increased in gastric cancer cells exposed
to mitomycin-C, which can induce DNA damage in many
cell types [31]. This finding suggests that DNA damage
might increase ATBF1 expression level because Ab can
also induce neuronal apoptosis through oxidative DNA
damage. Therefore, we treated cultured cortical neurons
with two different DNA-damaging drugs, etoposide and
homocysteine, which are used commonly as DNA-dama-
ging drugs for many cells types including neurons, and we
found that these two drugs significantly increased ATBF1
and p53 protein expression levels (Figure 2A). Next, we
measured the expression levels of ATBF1 mRNA in cul-
tured cortical neurons treated with Ab1-42 at an indicated
dose by semiquantitative real-time PCR analysis. As
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increased ATBF1 mRNA expression level in a dose-depen-
dent manner compared with the control, and etoposide
and homocysteine also increased ATBF1 mRNA expres-
sion level (Figure 2C). These findings indicate that an
increase in ATBF1 protein expression level induced by
Ab1-42, etoposide, and homocysteine is caused by an
increase in ATBF1 gene expression level.
Knockdown of ATBF1 in cultured cortical neurons
protected against Ab1-42-, etoposide-, and homocysteine-
induced neurotoxicity
Ab1-42, etoposide, and homocysteine induce death of
cultured cortical neurons in vitro [22]. Next, we exam-
ined whether ATBF1 mediates neuronal death after
treatment with Ab1-42, etoposide, and homocysteine.
For this purpose, we first decreased the ATBF1 expres-
sion level in primary cortical neurons by ATBF1
siRNA transfection. The cells were transfected with
ATBF1 siRNA-1 or control siRNA, as described in
“Experimental Procedures”. Forty-eight hours after
transfection, the ATBF1 protein expression level was
determined by Western blot analysis using an anti-
ATBF1 antibody. As shown in Figures 3A and 3C, the
transfection of ATBF1 siRNA-1 decreased the ATBF1
protein level by about 75% in cultured cortical neurons
compared with control siRNA transfection. This find-
ing indicates that endogenous ATBF1 can be efficiently
k n o c k e dd o w ni nt h e s ec e l l sb yt r a n s f e c t i o no fA T B F 1
siRNA-1. Next, we determined the effects of ATBF1
knockdown on neuronal survival against Ab1-42-, eto-
poside-, and homocysteine-induced neurotoxicity. Cul-
tured cortical neurons transfected with ATBF1 siRNA-
1 or control siRNA were treated with Ab1-42 at an
indicated dose, 1 μM etoposide, or 250 μM homocys-
teine for 16 h. Cell viability was then assessed using a
CellTitle-Glo luminescent cell viability assay kit. We
were able to detect differences in cell viability only by
ATBF1 siRNA-1 transfection compared with control
siRNA transfection. The percentage of surviving neu-
rons decreased in control-siRNA-transfected cells after
the treatment with Ab1-42, etoposide, or homocys-
teine. However, the percentage of surviving neurons
increased in ATBF1-siRNA-1-transfected cells com-
pared with control-siRNA-transfected cells after the
treatment with Ab1-42 (Figure 3B), etoposide, or
homocysteine (Figure 3D). These findings indicate that
ATBF1 could mediate neuronal death in response to
the treatment with Ab1-42, etoposide, or homocys-
teine. We also determined the effects of another
ATBF1 siRNA (ATBF1-siRNA-2) on neuronal survival
against Ab1-42-induced neurotoxicity, and obtained
similar result (Additional file 2). Therefore, we used
ATBF1 siRNA-1 to ATBF1 knockdown for the follow-
ing experiments.
ATBF1 mediated apoptotic function in cultured cortical
neurons against Ab1-42-induced neurotoxicity
To determine whether apoptosis is responsible for the
survival of cultured cortical neurons with decreased
ATBF1 expression levels, we analyzed DNA breaks by
terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) assay of ATBF1-siRNA- and
control-siRNA-transfected cells after Ab1-42 treatment.
Figure 4A shows representative images of TUNEL-posi-
tive cells and total nuclei. The treatment of control
siRNA-transfected cells with Ab1-42 resulted in a signif-
icant increase in the number of TUNEL-positive cells
compared with nontreatment (Figure 4A). However, the
percentage of TUNEL-positive cells among ATBF1-
siRNA-transfected cells treated with Ab1-42 was lower
than that among control-siRNA-transfected cells (Figure
4A), indicating that the knockdown of ATBF1 signifi-
cantly reduced the extent of Ab1-42-induced apoptosis.
Figure 1 ATBF1 protein expression level appears to decrease
in age-dependent manner in wild-type mice. It increased in the
brains of 17-month-old Tg2576 mice compared with age-matched
wild-type mice. Lysates were prepared from whole brains of 10- and
17-month-old Tg2576 (n = 6) and age-matched wild-type (WT) mice
(n = 6). The expression level of ATBF1 was determined by Western
blot analysis using the anti-ATBF1 antibody. A, representative
immunoblot is shown (upper panel), and bands were quantified by
densitometry, normalized to actin, and expressed as a value relative
to that in the 10-month-old WT mice as a control (lower graph). All
the values are presented as mean ± SEM. *p < 0.05 vs 10-month-old
WT mice (n = 6) and #p < 0.05 compared with those of 17-month-
old WT mice, as determined by one-way ANOVA followed by
Duncan’s test.
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increase in the percentage of TUNEL-positive cells (Fig-
u r e4 A ) .T oc o n f i r mt h e s ef i n d i n g s ,w ep e r f o r m e da
similar experiment, and caspase-3/7 activity was deter-
mined using a Caspase-Glo 3/7 assay kit. It has been
reported that Ab may lead to the induction of caspase-
3-mediated pathways that are involved in oxidative
stress [32]. The treatment of control siRNA-transfected
cells with Ab1-42 increased the activity of caspase-3/7
compared with nontreatment (Figure 4B). However, a
decreased activity of caspase-3/7 was detected in
ATBF1-siRNA-transfected cells treated with Ab1-42,
indicating that ATBF1 is at least one vital component
for the activation of caspase-3/7 in cultured cortical
neurons after Ab1-42 treatment.
Overexpression of ATBF1 itself in primary cortical
neurons did not induce apoptosis
Next, we examined whether overexpression of ATBF1
itself induces apoptosis in cultured cortical neurons.
The cells were transfected with HA-tagged full-length
human ATBF1 cDNA. Twenty-four hours after transfec-
tion, we performed TUNEL assay, and then counted
TUNEL-positive cells among HA-ATBF1-transfected
Figure 2 ATBF1 protein and mRNA expression levels increased in primary cortical neurons after treatment with Ab1-42 and DNA-
damaging drugs, namely, etoposide (Etop) and homocysteine (Hom). A, primary cortical neurons were seeded at a density of 1 × 10
6 cells/
ml in poly-d-lysine-coated 60 mm culture dishes. Three days after plating, the cells were treated for 16 h with 10 μMA b1-42, 1 μM etoposide, or
250 μM homocysteine, and the cells were then harvested. The expression levels of ATBF1 and p53 were determined by Western blot analysis
using the anti-ATBF1 and anti-p53 antibodies. A, a representative immunoblot is shown (upper panel), and bands were quantified by
densitometry, normalized to actin, and expressed as a value relative to that of the control (lower panel). B and C, primary cortical neurons were
treated for 16 h with 0, 2.5, 5, or 10 μMA b1-42 (B), or 250 μM homocysteine or 1 μM etoposide (C). ATBF mRNA expression level was
determined by real-time PCR analysis. The expression level of ATBF1 mRNA was normalized to the corresponding amount of actin mRNA and
expressed as a value relative to that of the control. All the values are presented as the mean ± SEM of three independent experiments. *p <
0.05, **p < 0.01, ***p < 0.001 vs control, as determined by Student’s t-test.
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were largely TUNEL-negative (95.2 ± 1.2%) (Figure 5).
This finding is consistent with our previous finding that
overexpression of ATBF1 in Neuro 2A cells (mouse
neuroblastoma cell line) by transfection of the HA-
ATBF1 expression vector did not induce apoptosis [25].
ATBF1-mediated neuronal death after Ab1-42 treatment
depended on ATM
Recent findings have shown that the ATM signaling
pathway is essential for Ab-induced neuronal death in
vitro and in vivo, and treatment with caffeine, an inhibi-
tor of ATM, protects cultured cortical neurons against
apoptosis induced by Ab1-42 [22]. Our previous data
have shown that the nuclear localization of ATBF1 is
suppressed by treatment with caffeine, indicating that
ATBF1 function could be regulated by ATM [25].
Moreover, it has also been reported that the ATBF1
gene is one of the target genes of ATM, which
phosphorylates ATBF1 at Ser1180 [26]. Therefore, we
examined whether ATBF1-mediated neuronal death
after Ab1-42 treatment is dependent on ATM. To deter-
mine whether caffeine can protect against neuronal
death induced by Ab1-42, we analyzed the effects of caf-
feine on cell viability (Figure 6A) and caspase-3/7 activ-
ity (Figure 6B). Cultured cortical neurons were
pretreated with 10 μM caffeine for 1 h and subsequently
treated with 2.5 μMa n d5μMA b1-42 for 16 h. The
cells were then assessed for cell viability and caspase-3/7
activity using CellTitle-Glo luminescent cell viability
assay and Caspase-Glo™ 3/7 assay kits, respectively. As
s h o w ni nF i g u r e s6 Aa n d6 B ,treatment with caffeine
decreased the number of dead cells treated with Ab1-42
(Figure 6A) and decreased caspase-3/7 activity (Figure
6B) compared with the nontreatment control. We also
tested the effect of KU55933, a specific inhibitor of
ATM [33], on cell viability. As shown in Additional file
3A, treatment with KU55933 decreased the number of
Figure 3 ATBF1 knockdown decreases the viability of primary cortical neurons upon treatment with Ab1-42, etoposide (Etop), or
homocysteine (Hom). A and C, knockdown of ATBF1 in primary cortical neurons. Primary cortical neurons were transfected with ATBF1 siRNA-1
or control siRNA for 48 h. After transfection, the cells were then incubated in the presence or absence of 10 μMA b1-42 (A), 1 μM etoposide (C),
or 250 μM homocysteine (C) for 16 h. The expression levels of ATBF1 and actin were determined by Western blot analysis using the anti-ATBF1
and anti-actin antibodies. B and D, primary cortical neurons were seeded at a density of 1 × 10
6 cells/ml in poly-d-lysine-coated 96-well plates.
Three days after plating, cells were transfected with ATBF1 siRNA-1 or control siRNA for 48 h, and the cells were then treated with 0, 2.5, 5, or 10
μMA b1-42 (B), 1 μM etoposide (D), or 250 μM homocysteine (D) for 16 h. Cell viability was determined using a CellTiter-Glo luminescent cell
viability assay kit and is shown as a percentage of surviving cells. All the values are presented as the mean ± SEM of three independent
experiments. *p < 0.05, **p < 0.01 vs control siRNA treatment. N.S., not significant, as determined by Student’s t-test.
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Page 5 of 14Figure 4 ATBF1 regulates apoptosis in primary cortical neurons in the presence of Ab1-42-induced neurotoxicity.A ,p r i m a r yc o r t i c a l
neurons were seeded at a density of 1 × 10
6 cells/ml in poly-d-lysine-coated 24-well glass plates. Three days after plating, the cells were
transfected with ATBF1 siRNA-1 or control siRNA for 48 h. After transfection, the cells were then incubated with 0, 2.5, or 10 μMA b1-42 for 16 h,
and apoptosis was analyzed by TUNEL assay. Cell nuclei were also stained with DAPI. Left panel: Representative images showing DAPI-stained
and TUNEL-positive cells. Right panel: quantification of TUNEL. TUNEL-positive neurons were counted from at least 400 neurons from five
randomly selected fields in three independent experiments. B, primary cortical neurons were seeded at a density of 1 × 10
6 cells/ml in poly-d-
lysine-coated 96-well plates. Three days after plating, cells were transfected with ATBF1 siRNA-1 or control siRNA for 48 h, and the cells were
then treated with 0, 2.5, or 5 μMA b1-42 for 16 h. Caspase-3/7 activity was determined using a Caspase-Glo™ 3/7 assay kit. All the values are
presented as the mean ± SEM of three independent experiments. *p < 0.05, **p < 0.01 vs control siRNA. N.S., not significant, as determined by
one-way ANOVA followed by Duncan’s test.
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teine at concentration as low as 1 μM. These findings
indicated that treatment with ATM inhibitors protect
against Ab1-42-, etoposide-, or homocysteine-induced
neuronal death. Next, we assessed the effect of siRNA-
mediated ATBF1 knockdown on Ab1-42-induced neuro-
nal death after treatment with caffeine or KU55933. As
shown in Figure 6C and Additional file 3, there are no
significant differences in the percentage of survival
between ATBF1 siRNA-transfected neurons with treat-
ment of caffeine or KU55933 and those without treat-
ment with caffeine or KU55933. These findings indicate
that ATBF1 is required for neuronal death in response
to Ab1-42 treatment, which could be dependent on
ATM signaling.
ATBF1 interacted with phosphorylated ATM
It is not known whether Ab1-42 can induce the phos-
phorylation of ATM in cultured cortical neurons. We
therefore analyzed the effect of Ab1-42 on the expres-
sion level of phosphorylated ATM (pATM) at Ser1981,
as an indicator of ATM activation, in cultured cortical
neurons. Cultured cortical neurons were treated with 10
μMA b1-42 for 3 h or with 1 μM etoposide for 1 h as
the positive control, and pATM expression level was
determined by Western blot analysis using a specific
antibody to ATM at Ser1981. We found an increase in
pATM levels after the treatments with Ab1-42 and eto-
poside (Figure 7A). To determine whether ATBF1 inter-
acts with pATM, coimmunoprecipitation analysis was
performed. Cultured cortical neurons were treated with
10 μMA b1-42 for 3 h or 1 μM etoposide for 1 h, and
then subjected to immunoprecipitation with anti-ATBF1
antibody-conjugated Protein G beads followed by immu-
noblotting with the anti-pATM antibody. As shown in
Figure 7B, ATBF1 interacted with pATM after treat-
ment with Ab1-42 or etoposide. Our findings suggest
that ATBF1 expression was enhanced by Ab1-42 and
DNA-damaging drugs (etoposide and homocysteine)
and increased the expression level of ATBF1, which in
turn activated ATM signaling responsible for neuronal
death through the binding of ATBF1 to pATM.
ATM was required for ATBF1 to activate
the p21 promoter
To determine the functional relationship between
ATBF1 and ATM, we carried out p21 (Waf1/Cip1) pro-
moter assay using ATM (+/+) and ATM (-/-) human
fibroblast cells. ATM has been shown to play a role in
the induction of DNA double strand breaks to arrest the
cell cycle via activation of p53, and ATBF1 activates the
p21 promoter in collaboration with p53 [27]. As shown
in Figure 8, irradiation with X-ray increased the p21
promoter activity in ATM (+/+) cells, but not in ATM
(-/-) cells, which is consistent with a previous finding
that p21 expression is not changed in ATM (-/-) cells
treated with the DNA-damaging drug etoposide [34].
Overexpression of ATBF1 increased the p21 promoter
activity in ATM (+/+) cells, but not in ATM (-/-) cells.
The combination of X-ray irradiation and overexpres-
sion of ATBF1 in ATM (+/+) cells synergistically
increased p21 promoter activity. Importantly, this effect
of ATBF1 on p21 promoter activity was abolished in
ATM (-/-) cells. This finding indicates that ATBF1
increases p21 promoter activity in an ATM-dependent
manner.
Discussion
Recently, cell-cycle-related molecules have been impli-
cated as required components in the mechanisms
underlying neuronal death in response to injury, stroke,
and neurodegenerative diseases including AD [35-38]
and transgenic mouse models of AD [19,20]. We have
previously reported that ATBF1 is highly expressed in
postmitotic neurons but not in neural progenitor cells
in the developing rat brain, and that its mRNA expres-
sion level is highest in the embryonic day 12.5 (E12.5)
brain [25]. Moreover, the overexpression of ATBF1
induces cell cycle arrest in mouse neuroblastoma,
human prostate cancer, and human breast cancer cell
Figure 5 Overexpression of HA-tagged ATBF1 itself in primary cortical neurons did not induce apoptosis. TUNEL of primary cortical
neurons transfected with HA-tagged ATBF1. The cells were transiently transfected with HA-tagged ATBF1. Twenty-four hours after transfection,
TUNEL was performed, and then the cells were stained with the anti-HA antibody to detect transfected HA-ATBF1. Scale bars: 25 μm.
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cortical neurons were seeded at a density of 1 × 10
6 cells/ml in poly-d-lysine-coated 96-well plates. Three days after plating, cells were
pretreated with 10 μM caffeine for 1 h, and subsequently treated for 16 h with 0, 2.5, or 5 μMA b1-42. Cell viability was determined using a
CellTiter-Glo luminescent cell viability assay kit (A), and caspase-3/7 activity was determined using a Caspase-Glo™ 3/7 assay kit (B). C, after
transfection as described in Fig 3B, cells were pretreated for 1 h with or without 10 μM caffeine, and then cells were further incubated with or
without 5 μMA b1-42 for 16 h. Cell viability was determined using a CellTiter-Glo luminescent cell viability assay kit. All the values are presented
as the mean ± SEM of three independent experiments. *p < 0.05, **p < 0.01 vs control siRNA. N.S., not significant, as determined by one-way
ANOVA followed by Duncan’s test.
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play critical roles in cell cycle arrest and proliferation. In
the present study, we found that the ATBF1 expression
level in the brains of 17-month-old wild-type mice
decreased compared with that in the brains of 10-
month-old wild-type mice. This finding is consistent
with our previous finding that ATBF1 mRNA expression
level gradually decreases with increasing age in the rat
brain [25]. However, ATBF1 expression was up-regu-
lated in the brains of 17-month-old Tg2576 mice com-
pared with that in the brains of age-matched wild-type
mice. In Tg2576 mice, diffuse plaques appear after 12
months, and their amount gradually increases with age
[30]. Therefore, we considered that the increase in
ATBF1 expression level was due to Ab,a n dw ef o u n d
that the treatment with Ab1-42 significantly increased
the expression levels of ATBF1 mRNA and protein in
cultured rat cortical neurons. The increase in ATBF1
expression level in the brains of 17-month-old Tg2576
mice could be triggered by the accumulation of
extracellular Ab similar to the Ab-mediated increase in
ATBF1 expression level observed in cultured cortical
neurons. In addition, the reason why ATBF1 remains
increased in 17-month-old Tg2576 mice could be that
Ab induces neurons to re-enter the cell cycle and
ATBF1 prevents this process from occurring.
Ab induces oxidative DNA damage. A previous study
showed that the expression level of ATBF1 is increased
in gastric cancer cells treated with mitomycin-C, which
can induce DNA damage in many cell types [31]. This
suggests that DNA damage might increase ATBF1
expression level. We, therefore, also examined whether
treatment with DNA-damaging drugs, namely, etoposide
and homocysteine, affects ATBF1 expression. Here, we
found that these DNA-damaging drugs significantly
increased the expression levels of ATBF1 mRNA and
protein in cultured rat cortical neurons. These findings
suggest that the up-regulated ATBF1 expression
observed in our in vivo and in vitro experiments could
be due to DNA damage induced by Ab.
It has been reported that the consequences of DNA
damage are the expression of cell-cycle-related proteins
[22,39,40] and activation of the family of phosphatidyli-
nositol-3 (PI3)-kinases that include the ATM protein,
which is involved in the regulation of cell cycle and
apoptosis by the phosphorylation of many downstream
Figure 7 A, phosphorylation of ATM after treatment of primary
cortical neurons with Ab1-42 or etoposide. Primary cortical
neurons were treated for 1 h with 10 μMA b1-42 or with 1 μM
etoposide (Etop). The cells were lysed, and the protein expression
levels of pATM, ATM, and actin were determined by Western blot
analysis using the anti-pATM, anti-ATM, and anti-actin antibodies. B,
ATBF1 interacts with pATM after treatment with Ab1-42 or
etoposide. Cultured cortical neurons were treated as described in A,
cell lysates were immunoprecipitated with the anti-ATBF1 antibody.
The immunoprecipitated complex was then subjected to
immunoblotting with the anti-pATM at Ser1891 antibody. Typical
bands representative of three independent experiments with similar
results are shown.
Figure 8 Effect of ATBF1 on activation of p21 promoter in X-
ray-irradiated ATM (+/+) and ATM (-/-) cells. ATM (+/+) and ATM
(-/-) cells were transfected with p21 promoter-luciferase, pRL-TK-
luciferase (as an internal control), and an indicated dose of HA-
ATBF1 vector or pCI-HA vector as a control. After 24 h, cells were
irradiated with a 2.5 Gy X-ray, and then luciferase activity was
measured after 12 h. All the values are presented as the mean ±
SEM of three independent experiments. **p < 0.01 vs not irradiated.
N.S., not significant, as determined by Mann-Whitney U-test with
Bonferroni Correction.
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Page 9 of 14substrates [41-43]. Therefore, one possibility is that
ATM could constitute a common pathway activated in
neuronal apoptosis after DNA damage. Recently, we
have found that ATM induces ATBF1 expression during
retinoicacid-induced neuronal differentiation of P19
cells by the activation and binding of CREB to a CRE
consensus site located in the ATBF1 promoter (unpub-
lished data). It has also been reported that the ATBF1
gene is one of the target genes of ATM that phosphory-
lates ATBF1 at Ser1180 [26]. These observations suggest
that the activation of ATM highly correlates with the
function and expression of ATBF1 as a gene regulatory
factor. In this study, we observed that treatment with
Ab1-42 and etoposide rapidly posphorylates ATM at Ser
1981, and that ATBF1 interacts with pATM in cultured
cortical neurons. Taken together, ATM activation
induced by Ab and DNA-damaging drugs may induce
ATBF1 expression.
In this study, we also examined the effect of ATBF1
on neuronal death and apoptosis induced by Ab1-42,
etoposide, and homocysteine in cultured cortical neu-
rons, and we found that the knockdown of ATBF1 by
ATBF1 siRNA transfection significantly reduced the
extent of cell death and apoptosis induced by Ab1-42,
etoposide, homocysteine. In addition, the knockdown of
ATBF1 attenuated the activation of caspase-3/7. These
findings suggest that the increased ATBF1 expression
level may mediate apoptotic function in cultured cortical
neurons against Ab1-42-induced neurotoxicity. It has
been reported that Ab and DNA-damaging drugs induce
the expression and activation of p53 which plays an
important role in promoting apoptosis in cultured neu-
rons [22,44]. Therefore, the increased ATBF1 expression
level might simultaneously activate p53 to promote cell
death, because ATBF1 interacts with p53 [27]. We also
found in this study that ATBF1-mediated neuronal
death is dependent on ATM signals because the block-
age of ATM by treatment with ATM inhibitors, caffeine
and KU55933, abolished ATBF1 functions in neuronal
death. This finding is in agreement with our previous
finding that caffeine treatment inhibits the translocaliza-
tion of ATBF1 to the nucleus in P19 cells [25]. Further
studies are necessary to characterize the role of ATBF1
in AD pathogenesis such as whether ATBF1 expression
is altered in the AD brain.
Conclusions
In conclusion, the increase in ATBF1 expression level
observed in the brain of 17-month-old Tg2576 mice
compared with age-matched wild-type mice could be
caused by DNA damage induced by Ab1-42, which in
turn activates the ATM signaling responsible for neuro-
nal death, indicating that ATBF1 plays an important
role in neuronal death in response to Ab1-42, etoposide,
and homocystein, and it may be a useful target in the
development of drugs to suppress the neuronal death
induced by Ab1-42.
Methods
Tg2576 mice
Female Tg2576 mice, an animal model of amyloid
deposition, overexpressing human APP695 with the
Swedish mutation K670N/M671, were obtained from
Taconic (Germantown, NY). All the experiments were
performed in accordance with the Guidelines for Animal
Experiments of the Animal Experimentation Committee
of the National Center for Geriatrics and Gerontology.
Cell cultures
Cerebral cortical neurons were obtained from E17 Spra-
gue-Dawley rats and cultured as described previously [45].
Briefly, embryonic brains were dissected, stripped of
meninges, and minced with forceps. The minced tissue
was incubated in 0.25% trypsin and 2 mg/ml DNase I in
phosphate-buffered saline (PBS) at 37°C for 15 min. The
fragments were then dissociated into single cells by pipet-
ting. The dissociated cells were suspended in DMEM/F-12
medium (50:50%) containing N2 supplements and 7.5%
bovine albumin fraction V, and plated onto poly-d-lysine-
coated 60 mm dishes at a density of 1 × 10
6/ml. These
cells were used on day 4 of plating for further experiments.
The immortalized fibroblast cell line AT22IJE-T was ori-
ginally established from primary ataxia-telangiectasia (A-
T) patient fibroblasts [46]. The cells were transfected with
either the pEBS7 or pEGS7-YZ ATM vector to obtain
AT22IJE-T/pEBS7 (ATM -/-) and AT22IJE-T/YZ5 (ATM
+/+) cells, respectively [47]. Cells were maintained in
DMEM containing 15% fetal bovine serum (FBS), 2 mM
glutamine, 100 μg/ml hygromycin B, 100 U/ml penicillin,
and 0.1 mg/ml streptomycin.
RNA extraction and real-time PCR
Total RNA was isolated from primary cortical neurons
using an RNeasy plus mini kit (Qiagen, Valencia, CA)
following the manufacturer’si n s t r u c t i o n s .R e v e r s et r a n -
scription was performed using 1 μgo ft o t a lR N Au s i n g
a PrimeScript RT reagent kit (Takara, Tokyo, Japan).
Real-time PCR was carried out using the SYBR Premix
Ex Taq system and Thermal Cycler Dice Real-Time sys-
tem (Takara). The expression of the ATBF1 gene was
normalized with the corresponding amount of actin
mRNA using the comparative threshold cycle method
following the manufacturer’s protocols. Amplification
was performed using the following primers (sense and
antisense): ATBF1 (5’-CAAAACTTCTGCTGCCCTTC-
3’ and 5’-GGCTTGTCTCAAGGTGC-TTC-3’) and actin
(5’-CATCCGTAAAGACCTCTATGCCAAC-3’ and
5’-ATGGA-GCCACCGATCCACA-3’).
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The synthetic Ab1-42 peptide was purchased from Pep-
tide Institute (Osaka, Japan), dissolved in 0.1% NH3 to
the final concentration of 1 mM, and stored at -80°C
until use. To confirm the state of the Ab1-42 peptide,
we performed Western blot analysis. Briefly, a stored
Ab1-42 peptide was subjected to 16% Tris-Tricine Gel
(Invitrogen) electrophoresis and transferred to polyviny-
lidene difluoride (PVDF) membranes (Millipore, Biller-
ica, MA). These membranes were incubated with a
primary antibody against mouse monoclonal human Ab
(6E10; Covance, Emeyryville, CA). For detection, the
membrane was incubated with a horseradish-peroxi-
dase-conjugated Ig anti-mouse antibody. Immunoreac-
tion signals were visualized with ECL™ or ECL Plus™
Western blotting detection reagent (GE Healthcare, Pis-
cataway, NJ) and exposed to the LAS-3000 Mini Bio-
imaging Analyzer System (FUJIFILM Co., Tokyo, Japan).
Western blot analysis
The cells were washed with PBS and homogenized in
lysis buffer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1
mM EDTA, 1% Triton X-100) containing a protease
inhibitor cocktail (Roche, Mannheim, Germany). The
homogenates were rocked at 4°C for 30 min and centri-
fuged at 13,000 × g at 4°C for 30 min to remove cell
debris. The resulting supernatant was collected and pro-
tein concentration was determined using a BCA protein
assay kit (Pierce, Rockford, IL). Equal amounts of pro-
tein were subjected to 7.5% or 5-20% gradient SDS poly-
acrylamide gel electrophoresis, and separated products
were transferred to PVDF membranes. These mem-
branes were then blocked with 5% skim milk in 10 mM
Tris-HCl (pH 7.5), 150 mM NaCl, and 0.1% Tween 20
for 1 h at room temperature or overnight at 4°C. These
membranes were incubated with primary antibodies,
namely, the anti-ATBF1 (AT-6) antibody (1:1000; MBL,
Nagoya, Japan), anti-p53 antibody (1:1000; Cell Signal-
ing, Cambridge, UK), anti-ATM antibody (1:1000; Gene
Tex, Irvine, CA), anti-ATM kinase pS1981 antibody
(1:1000; Rockland, Gilbertsville, PA), or anti-actin anti-
body (1:2,000; Sigma, Saint Louis, MO). The membranes
were washed, and then incubated with the appropriate
secondary antibody conjugated to horseradish peroxi-
dase. Immunoreaction signals were visualized with
ECL™ or ECL Plus™ Western blotting detection
reagent and exposed to the LAS-3000 Mini Bio-imaging
Analyzer System. Signal intensity was determined using
MultiGauge software (FUJIFILM).
RNA interference
Endogenous ATBF1 was knocked down using prede-
signed Stealth™siRNA against ATBF1 (ATBF1 siRNA)
and Stealth siRNA negative control (control siRNA)
from Invitrogen (Carlsbad, CA). The ATBF1 siRNAs
sequences are as follows: ATBF1-siRNA-1 sense (5’-
UAC ACU GGU CAG ACC ACU GUC CUU G-3’)a n d
antisense (5’-CAA GGA CAG UGG UCU GAC CAG
UGU -3’). ATBF1-siRNA-2 sense (5’- UAC ACU GGU
CAG ACC ACU GUC CUU G-3’)a n da n t i s e n s e( 5 ’-
TAC ACT GGT CAG ACC ACT GTC CTT G-3’). The
primary cultured neurons were transiently transfected
with 50 nM ATBF1 siRNA or with control siRNA using
Lipofectamine RNAiMAX (Invitrogen) in accordance
with the manufacturer’s instructions. The knockdown
effects were examined after 48 h of incubation. The cul-
tures were then processed for Western blot analysis, cell
viability analysis and terminal deoxynucleotidyl transfer-
ase-mediated dUTP nick-end labeling (TUNEL) assay 16
h after Ab1-42 treatment.
Cell viability analysis
Neuronal viability was evaluated by CellTiter-Glo lumi-
nescent cell viability assay (Promega, Madison, WI),
which is a method to determine the number of viable
cells in culture based on the quantitation of ATP pre-
sent, which indicates the presence of metabolically
active cells. Briefly, primary cortical neurons were
seeded onto poly-d-lysine-coated 96-well plates, and
incubated for 72 h. For the ATBF1 knockdown experi-
ment, the cells were transfected with ATBF1 siRNA or
with control siRNA for 48 h as described above, cells
were then treated with Ab1−42, etoposide, or homocys-
teine at indicated doses for 16 h. After treatment, a
volume of CellTiter-Glo Reagent was added to each well
equal to the volume of cell culture medium. Then, the
contents were mixed for 2 min on a shaker to induce
cell lysis and the plates were incubated at room tem-
perature for 10 min in the dark. Cellular luminescence
intensity was measured using a GLOMAX 96-microplate
luminometer (Promega).
Plasmid constructs
The ATBF1 expression vector of an 11 kb full-length
human cDNA [23] was inserted into the pCI vector
(Promega) with an HA-tagged sequence at the 5’-termi-
nus of the inserted sequence (HA-ATBF1) [25]. The 2.4
kb fragment upstream from the TATA-box of the
human p21 (Waf1/Cip1) genomic fragment was sub-
cloned into the basic luciferase reporter pGV-B vector
(Toyo Ink Co., Ltd., Tokyo, Japan) [48].
TUNEL assay
Apoptosis was assessed by TUNEL using an ApopTag
Fluorescein Direct In Situ Apoptosis Detection kit in
accordance with the manufacturer’s instructions (Chemi-
con, Temecula, CA). Briefly, cells were fixed with 1% par-
aformaldehyde in PBS for 10 min at room temperature
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at -20°C. Cells were then washed with PBS. Fluores-
cein-conjugated nucleotide and TdT enzyme were
added to the cells, which were then incubated for 1 h
at 37°C. Nuclei were stained with DAPI. Images were
obtained using an AX70 fluorescence microscope
(Olympus). The percentage of apoptotic cells was
determined as the ratio of the number of DAPI-
TUNEL-double-positive cells with respect to the total
number of DAPI-positive cells. For the overexpression
of ATBF1 in cultured cortical neurons, the neurons
were transiently transfected with 0.5 μgH A - A T B F 1
using FuGENE HD (Roche) in accordance with the
manufacturer’s instructions. Twenty-four hours after
transfection, TUNEL was performed as described in
above. After TUNEL, the neurons were incubated with
the primary antibody against HA-tag (MBL) for 1 h at
RT. The secondary antibody was Alexa-594-conjugated
goat anti-rabbit IgG (Molecular Probes). Images were
obtained using an AX70 fluorescence microscope
(Olympus).
Caspase-3/7 activity assay
Caspase-3/7 activity was assayed using a Caspase-Glo™
3/7 assay kit (Promega), in accordence with the manu-
facturer’s instructions. Briefly, primary cortical neurons
were seeded on 96-well plates at a density of 1 × 10
6
cells/ml. After 3 days, the cells were treated with Ab1-
42 or DNA-damaging drugs. Caspase-Glo™ 3/7 reagent
was then added to each well, and the plates were incu-
bated at room temperature for 1 h. Cellular lumines-
cence was measured using a GLOMAX 96-microplate
luminometer (Promega).
Immunoprecipitation
Primary cortical neurons were grown in 10 cm dishes.
After reaching 50-70% confluence, the cells were treated
with 10 μMA b1−42 or 1 μM etoposide for an indicated
time. After incubation, the cells were washed twice with
PBS, lysed in 1 ml of lysis buffer (10 mM Tris-HCl (pH
7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 50
mM NaF, and 100 uM sodium orthovanadate) contain-
ing protease inhibitor cocktail, and centrifuged at 13,000
× g at 4°C for 20 min. The resulting supernatant was
immunoprecipitated overnight with a specific antibody
against ATBF1 (AT-6) in the presence of protein G
beads (Pierce) at 4°C. The immune complexes were
washed four times with lysis buffer. The samples were
subjected to 5-20% gradient SDS polyacrylamide ge elec-
trophoresis, and separated products were transferred to
a PVDF membrane and subjected to immunoblotting
with a specific antibody against phosphorylated-ATM
(pATM) at Ser 1981.
X-ray irradiation and p21 promoter assay
ATM (+/+) and ATM (-/-) cells were transfected with
p21 promoter-luciferase, pRL-TK-luciferase (as an inter-
nal control), and an indicated dose of the HA-ATBF1
vector or pCI-HA vector as the control using Lipofecta-
mine 2000 (Invitrogen) in accordance with manufac-
turer’s instructions. After 24 h, the cells were irradiated
with X-ray at 2.5 Gy using a Softex M-80WE X-ray gen-
erator (SOFTEX, Japan) operating at 80 kv and 10 mA
for 25 min with a copper shield. Nonirradiated dells
were used as control. After 12 h, luciferase activity was
measured using the Dual Luciferase Reporter Assay sys-
tem (Promega) in accordance with the manufacturer’s
instructions.
Statistical analysis
Statistical analysis was performed using a statistical
package, GraphPad prism software (GraphPad Software,
San Diego, CA). All values are presented as the mean ±
SEM of at least three independent experiments.
Additional material
Additional file 1: Western blot analysis of Ab1-42 peptide used in
our experiments. The stored Ab1-42 peptide was diluted with culture
medium to the final concentration of 5 μM, and then 0.5 (lane 1), 1 (lane
2), or 2.5 μl (lane 3) was loaded to 16% Tris-Tricine gel and probed with
the monoclonal antibody 6E10 (recognizing residues 1-17 of Ab).
Additional file 2: Effect of another ATBF1 siRNA (ATBF1 siRNA-2) on
the viability of primary cortical neurons upon treatment with Ab1-
42. A, Primary cortical neurons were transfected with ATBF1 siRNA-2 or
control siRNA for 48 h. After transfection, the cells were then incubated
in the presence or absence of 5 μMA b1-42 for 16 h. The expression
levels of ATBF1 and actin were determined by Western blot analysis
using the anti-ATBF1 and anti-actin antibodies. B, After transfection as
described in Figure 3B, the cells were treated with or without 5 μMA b1-
42 for 16 h. Cell viability was determined using a CellTiter-Glo
luminescent cell viability assay kit and is shown as a percentage of
surviving cells. All the values are presented as the mean ± SEM of three
independent experiments. *p < 0.01 vs control siRNA treatment. N.S., not
significant, as determined by Student’s t-test.
Additional file 3: A, KU55933, a specific ATM inhibitor, shows a
neuroprotective effect against Ab 1-42-, etoposide-, and
homocysteine-induced neurotoxicity. Primary cortical neurons were
seeded at a density of 1 × 10
6 cells/ml in poly-d-lysine-coated 96-well
plates. Three days after plating, cells were pretreated with 0, 1, 5, or 10
μM KU55933 for 1 h, and subsequently treated for 16 h with 5 μMA b1-
42, 1 μM etoposide (Etop), or 250 μM homocysteine (Hom). Cell viability
was determined using a CellTiter-Glo luminescent cell viability assay kit.
B, after transfection as described in Figure 3B, cells were pretreated for 1
h with or without 1 μM KU55933, and then cells were further incubated
with or without 5 μMA b1-42 for 16 h. Cell viability was determined
using a CellTiter-Glo luminescent cell viability assay kit. All the values are
presented as the mean ± SEM of three independent experiments. *p <
0.001 vs control siRNA. N.S., not significant, as determined by one-way
ANOVA followed by Duncan’s test.
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